Standard chemotherapy

Phase 3Small molecule

Standard chemotherapy is one of 169 small molecule programs targeting Fallopian Tube Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

168

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube CancerActive, not recruiting

Breast CancerCompleted

Bladder CancerActive, not recruiting

Advanced Solid TumorsNot yet recruiting

Relapsed/refractoryRecruiting

Microsatellite Stable Metastatic Colorectal CancerRecruiting

Gastric Cancer Peritoneal MetastasesRecruiting

Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruiting

PtosisActive, not recruiting

Fallopian Tube CancerPreclinical

Active, not recruiting

Breast CancerPhase 3

Completed

Bladder CancerPreclinical

Active, not recruiting

Advanced Solid TumorsPhase 2

Not yet recruiting

Relapsed/refractoryPhase 2

Recruiting

Microsatellite Stable Metastatic Colorectal CancerPhase 2

Recruiting

Gastric Cancer Peritoneal MetastasesPhase 3

Recruiting

Advanced Solid Tumors With Neuroendocrine DifferentiationPhase 2

Not yet recruiting

PtosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Standard chemotherapy

Roche

Phase 3

7 2

Adenocard

Astellas

Preclinical

2 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Treatment

NCT06810791

Q2 2027

Phase 2Recruiting

Colorectal Cancer

NCT06856187

Phase 1/2Recruiting

Relapsed/refractory

NCT03319901

Q3 2027

Phase 2Not yet recruiting

Advanced Solid Tumors With Neuroendocrine Differentiation

NCT06531291

Q4 2027

Phase 3Not yet recruiting

Oligometastatic Disease

NCT06141070

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT07260058

Clinical

Trials by Indication[1]

Breast Cancer7 trials

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Completed· Roche logo

Roche·Phase 3·NCT00281697·684 enrolled

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

Completed·PPeking Union Medical College Hospital·Phase 3·NCT02483767·98 enrolled

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Recruiting·FFudan University·Phase 3·NCT07019363·1,903 enrolled

Show 4 more trials

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

Not yet recruiting·FFudan University·Phase 3·NCT05889871·916 enrolled

A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00559754·72 enrolled

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 4·NCT04031885·4 enrolled

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00717405·52 enrolled

Colorectal Cancer2 trials

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06856187·119 enrolled

Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)

Unknown status·FFudan University·Phase 3·NCT02965248·147 enrolled

Pancreatic Cancer2 trials

Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy

Unknown status·FFudan University·Phase 3·NCT03398291·300 enrolled

Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

Unknown status·SSofia Perea, Director Clinical Trials Unit.·Phase 2·NCT01394120·60 enrolled

Small Cell Lung Cancer2 trials

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Completed·—·Phase 2·NCT04263051·60 enrolled

Bevacizumab in Extensive Small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT00930891·143 enrolled

Treatment2 trials

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Recruiting·NNanfang Hospital, Southern Medical University·Phase 3·NCT06810791·876 enrolled

LOTCOL Study: Local Treatment of Colo-rectal Liver Met

Terminated·OOslo University Hospital·N/A·NCT01867918·3 enrolled

28 more indications

Ovarian Cancer2 trials

Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines

Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 2·NCT03622931·21 enrolled

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Active, not recruiting·CCordgenics, LLC·Phase 3·NCT03949283·150 enrolled

Mesothelioma2 trials

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT00651456·448 enrolled

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Completed·PPrECOG, LLC.·Phase 3·NCT04334759·214 enrolled

Advanced Solid Tumors With Neuroendocrine Differentiation1 trial

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Not yet recruiting·RRenJi Hospital·Phase 2·NCT06531291·80 enrolled

Lymphoma1 trial

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT00269113·360 enrolled

Colonic Cancer1 trial

Proactive Management of Endoperitoneal Spread in Colonic Cancer

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT02974556·140 enrolled

Colon Cancer1 trial

Adjuvant HIPEC in High Risk Colon Cancer

Completed·—·Phase 3·NCT02231086·204 enrolled

Oligometastatic Disease1 trial

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Not yet recruiting·VVastra Gotaland Region·Phase 3·NCT06141070·240 enrolled

Completed·—·Phase 3·NCT00718354·740 enrolled

Relapsed/Refractory1 trial

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Recruiting·—·Phase 1/2·NCT03319901·82 enrolled

Refractory Cancer1 trial

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

Completed·IInstitut Curie·Phase 2·NCT01771458·742 enrolled

Acute Myeloid Leukemia1 trial

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Completed·UUniversity of Ulm·Phase 3·NCT00893399·600 enrolled

Fallopian Tube Cancer1 trial

Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00293293·43 enrolled

Post-surgical1 trial

TAilored Post-Surgical Therapy in Early Stage NSCLC

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2/3·NCT00775385·152 enrolled

Gastric Carcinoma1 trial

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04065139·66 enrolled

Lung Cancer1 trial

A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Terminated· Roche logo

Roche·Phase 2·NCT00642824·3 enrolled

Ptosis1 trial

Use of the MiCK Assay for Apoptosis in AML

Completed·PPierian Biosciences··NCT00286845·50 enrolled

Non-Small Cell Lung Cancer1 trial

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT01951586·226 enrolled

Clear Cell Adenocarcinoma1 trial

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT03405454·46 enrolled

Growth1 trial

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Completed· Amgen logo

Amgen·Phase 3·NCT00911170·847 enrolled

Allogeneic Stem Cell Transplantation1 trial

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT04184505·274 enrolled

Bladder Cancer1 trial

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05547516·140 enrolled

Chemotherapy1 trial

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Completed· Roche logo

Roche·Phase 2·NCT00643565·154 enrolled

Osteosarcoma1 trial

Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma

Unknown status·TTata Memorial Hospital·Phase 2/3·NCT00691236·60 enrolled

Microsatellite Stable Metastatic Colorectal Cancer1 trial

Phase 2 Study of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1, Chemotherapy and Target Therapy for Metastatic Colorectal Cancer(iPULSAR-CRC)

Recruiting·FFudan University·Phase 2·NCT06841159·116 enrolled

Malignant Solid Tumor1 trial

First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors

Terminated· Genmab logo

Genmab·Preclinical·NCT06391775·21 enrolled

Gastric Cancer Peritoneal Metastases1 trial

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric

Recruiting·MMagnus Nilsson·Phase 3·NCT07304271·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Standard chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Standard chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer7 trials

Colorectal Cancer2 trials

Pancreatic Cancer2 trials

Small Cell Lung Cancer2 trials

Treatment2 trials

Ovarian Cancer2 trials

Mesothelioma2 trials

Advanced Solid Tumors With Neuroendocrine Differentiation1 trial

Lymphoma1 trial

Colonic Cancer1 trial

Colon Cancer1 trial

Oligometastatic Disease1 trial

Randomized Controlled Trial1 trial

Advanced Solid Tumors1 trial

Esophageal Cancer1 trial

Relapsed/Refractory1 trial

Refractory Cancer1 trial

Acute Myeloid Leukemia1 trial

Fallopian Tube Cancer1 trial

Post-surgical1 trial

Gastric Carcinoma1 trial

Lung Cancer1 trial

Ptosis1 trial

Non-Small Cell Lung Cancer1 trial

Clear Cell Adenocarcinoma1 trial

Growth1 trial

Allogeneic Stem Cell Transplantation1 trial

Bladder Cancer1 trial

Chemotherapy1 trial

Osteosarcoma1 trial

Microsatellite Stable Metastatic Colorectal Cancer1 trial

Malignant Solid Tumor1 trial

Gastric Cancer Peritoneal Metastases1 trial

References

Drug Info

Quick Facts

Related News